Identifier |
20230314_nanos_posters_293 |
Title |
A First-in-Human Phase 1 Randomized, Singleascending Dose Study of VB421 (lonigutamab), an Anti-IGF-1R Monoclonal Antibody, in Healthy Volunteers |
Creator |
Gregory Keenan; Timothy Mack; Naveen Daryani; Stephen Thomas |
Affiliation |
(GK) (TM) Valenzabio; (ND) (ST) Valenza Bio Inc. |
Subject |
Graves' Disease; Neuro-ophthalmology & Systemic Disease (eg. MS, MG, Thyroid); Orbit/Ocular Pathology |
Description |
Monoclonal antibodies targeting insulin-like growth factor 1 receptor (IGF-1R) have been shown to be effective in the treatment of thyroid eye disease (TED). However, currently approved biologics are only available intravenously (IV). Additional therapies that support alternative routes of administration are needed, including therapies that can be subcutaneously (SC) administered. VB421 is a monoclonal antibody against IGF-1R that targets a unique epitope with picomolar affinity. The high affinity and resulting pharmacokinetic properties of VB421 may allow for SC administration in the treatment of TED. |
Date |
2023-03-14 |
Language |
eng |
Format |
application/pdf |
Type |
Text |
Source |
2023 North American Neuro-Ophthalmology Society Annual Meeting |
Relation is Part of |
NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
Collection |
Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
Publisher |
North American Neuro-Ophthalmology Society |
Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
Rights Management |
Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
ARK |
ark:/87278/s6wsrf05 |
Setname |
ehsl_novel_nam |
ID |
2335498 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6wsrf05 |